Business Context and Reporting Period
This Form 8-K is a current report filed by NanoViricides, Inc. (NNVC) on September 25, 2025. The filing discloses material events regarding executive compensation extensions and amendments to the company's line of credit facility. The company is incorporated in Delaware and its common stock trades on the NYSE American.
Key Financial Metrics and Agreements
The filing does not provide standard financial performance metrics such as revenue, net income, operating cash flow, or liquidity ratios. Instead, it details specific financial obligations and credit facilities:
- Executive Compensation:
- Dr. Anil Diwan (President): Base annual salary of $400,000; granted 10,204 shares of Series A Preferred Stock vesting quarterly through June 30, 2026; eligible for 6 months' salary severance if terminated without cause.
- Meeta Vyas (CFO): Base compensation of $10,800 per month; eligible for health insurance reimbursement up to 50% of costs, capped at $2,500 per month.
- Debt Facility:
- Lender: Dr. Anil Diwan (Company President/CEO).
- Maximum Amount: Increased to $3,000,000.
- Interest Rate: Fixed at 12%.
- Maturity Date: Extended to March 31, 2027.
- Collateral: Open End Mortgage Deed on company real property and Chattel Mortgage on equipment/fixtures.
Material Changes Versus Prior Period
The filing outlines the following material changes compared to prior agreements:
- Employment Terms: Both the President and CFO entered into extension agreements effective July 1, 2025, extending their terms through June 30, 2026. The CFO's agreement includes a new specific amendment regarding health insurance reimbursement.
- Debt Capacity and Term: The line of credit was increased from $2 million to $3 million (amended September 23, 2024) and the maturity date was extended from March 31, 2026, to March 31, 2027 (amended July 25, 2025).
Outlook, Risks, and Contingencies
Management Commentary and Risks:
- Related Party Transactions: The company relies on a line of credit provided by its own President and CEO, creating a related-party dependency for liquidity.
- Collateral Risk: The company's real property and equipment are pledged as collateral for the $3 million credit facility.
- Executive Retention: The extensions and equity grants are designed to ensure leadership continuity and provide incentives for the company's success.
- Severance Contingency: The company has a defined liability of six months' salary for the President in the event of termination without cause.
Guidance: The filing does not contain forward-looking financial guidance or revenue projections.
Key Facts for Investor Verification
- Verify the current utilization amount of the $3 million line of credit and whether any drawdowns have occurred.
- Confirm the status of the collateral (real property and equipment) pledged to Dr. Diwan.
- Review the vesting schedule and current market value of the 10,204 Series A Preferred Stock shares granted to Dr. Diwan.
- Assess the company's cash runway given the reliance on a related-party loan with a 12% interest rate.